Skip to Main Content
Contribute Try STAT+ Today

We suspect we’re not the only ones who find it challenging to keep up with the many experiments that are CRISPR’ing seemingly every disease under the sun in mice, human cells, and other experimental systems, even human embryos. So we’re doing it for you: STAT has created a searchable CRISPR Trackr.

It lists studies from research journals, company announcements, and preprints, chosen because they reported a key advance in either the genome-editing technology or the diseases that might be treated with it. It also links to the research papers, though not all are open access (sorry). We’re not including everything, but we hope CRISPR Trackr gives you a sense of how quickly things are moving. (We’ve stopped updating the Trackr as of January 2021.)

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.